Enhanced efficacy of the novel recombinant clone VasSF in a mouse model of antineutrophil cytoplasmic antibody-associated vasculitis
Clinical and Experimental Immunology · 2024
DOI: 10.1093/cei/uxad140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2024. Verfasst von Minako Koura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Animal Models for Human Diseases, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Saito-Asagi, Ibar…. Hauptthemen laut MEDLINE: Antibodies, Antineutrophil Cytoplasmic, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Chiba University, Japan Agency for Medical Research and Development, Japan Science and Technology Agency.
Abstract (Originalsprache)
Based on the efficacy of intravenous immunoglobulin (IVIg) for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), we developed a recombinant single-chain-fragment variable clone, VasSF, therapeutic against AAV in a mouse model (SCG/Kj mice). VasSF is thought to bind to vasculitis-associated apolipoprotein A-II (APOA2) as a target molecule. VasSF is a promising new drug against AAV, but difficulties in the yield and purification of VasSF remain unresolved. We produced monomers of new VasSF molecules by modifying the plasmid structure for VasSF expression and simplifying the purification method using high-performance liquid chromatography. We compared the therapeutic effects between 5-day continuous administration of the monomers, as in IVIg treatment, and single shots of 5-day-equivalent doses. We also evaluated the life-prolonging effect of the single-shot treatment. Two-dimensional western blots were used to examine the binding of VasSF to APOA2. Our improved manufacturing method resulted in a 100-fold higher yield of VasSF than in our previous study. Monomerization of VasSF stabilized its efficacy. Single shots of a small amount (1/80 000 of IVIg) produced sufficient therapeutic effects, including decreased glomerular crescent formation, a decreasing trend of serum ANCA against myeloperoxidase (MPO-ANCA), decreases in multiple proinflammatory cytokines, and a trend toward prolonged survival. Two-dimensional western blots confirmed the binding of VasSF to APOA2. The newly produced pure VasSF monomers are stable and therapeutic for AAV with a single low-dose injection, possibly by removing vasculitis-associated APOA2. Thus, the new VasSF described herein is a promising drug against AAV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Animal Models for Human Diseases, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Saito-Asagi, Ibaraki City, Osaka, Japan.
- Department of Research and Development, A-CLIP Institute, Chyuo-ku, Chiba City, Chiba, Japan.
- Laboratory of Infectious Diseases, Asia International Institute of Infectious Disease Control, Teikyo University, Itabashi-ku, Tokyo, Japan.
- Interferon & Host-defense Laboratory, Louis Pasteur Center for Medical Research, Sakyo-ku, Kyoto, Japan.
- Department of Allergy and Clinical Immunology, Chiba University Graduate School of Medicine, Chuo-ku, Chiba, Chiba, Japan.
- Division of Co-creative Research in Disaster Therapeutics, Chiba University Research Institute of Disaster Medicine, Chuo-ku, Chiba City, Chiba, Japan.
ORCID-Profile: Osamu Suzuki
Förderung
- Chiba University
- Japan Agency for Medical Research and Development
- Japan Science and Technology Agency
Zitieren
APA
Koura, M., Kameoka, Y., Kishi, F., Yamakawa, Y., Ito, F., Sugamata, R., Doi, Y., Uno, K., Nakayama, T., Miki, T., Nakajima, H., Suzuki, K., & Suzuki, O. (2024). Enhanced efficacy of the novel recombinant clone VasSF in a mouse model of antineutrophil cytoplasmic antibody-associated vasculitis. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxad140
Vancouver
Koura M, Kameoka Y, Kishi F, Yamakawa Y, Ito F, Sugamata R, et al. Enhanced efficacy of the novel recombinant clone VasSF in a mouse model of antineutrophil cytoplasmic antibody-associated vasculitis. Clinical and Experimental Immunology. 2024. doi:10.1093/cei/uxad140
BibTeX
@article{Koura2024,
author = {Koura, Minako and Kameoka, Yosuke and Kishi, Fukuko and Yamakawa, Yoshio and Ito, Fuyu and Sugamata, Ryuichi and Doi, Yuko and Uno, Kazuko and Nakayama, Toshinori and Miki, Takashi and Nakajima, Hiroshi and Suzuki, Kazuo and Suzuki, Osamu},
title = {Enhanced efficacy of the novel recombinant clone VasSF in a mouse model of antineutrophil cytoplasmic antibody-associated vasculitis},
journal = {Clinical and Experimental Immunology},
year = {2024},
doi = {10.1093/cei/uxad140}
}
EUVIMED